ASX Announcements

Living Cell Technologies (ASX: LCT) (OTCQB: LVCLY) (“LCT” or “the Company”) is pleased to advise that Mr David Hainsworth has been appointed to Executive Chairman of LCT by the Board of Directors.

Living Cell Technologies is pleased to provide its quarterly activities report and appendix 4C for the period ended 31 December 2022.

The securities of LCT have been placed in a trading halt, pending the release of an announcement in relation to a capital raising mandate that includes a placement and rights issue.

Living Cell Technologies Limited today announced the half yearly report for the six months ended 31 December 2022. 

Living Cell Technologies continues to advance its mission of improving the wellbeing of people with serious

diseases by discovering, developing, and commercialising novel treatments for debilitating conditions

such as Parkinson’s disease.

Living Cell Technologies Limited is pleased to announce that it has executed a capital raise mandate with Alignment Capital Pty Ltd to raise up to approximately A$2.5M by way of three distinct funding initiatives:

• a placement for A$750,000;

• a non-renounceable rights issue entitlement offer, and shortfall offer by way of prospectus to raise circa A$1.2M; and

• a post rights issue over allotment offer to raise an additional A$562,500.